Policy & Regulation

The DEA has launched a portal for state-licensed medical cannabis registration, offering a rare path to federal legitimacy. However, with House Republicans moving to bottle up broader rescheduling and a 60-day window closing fast, operators face both a race for federal protection and an increasingly uncertain climate in D.C.

The Department of Justice moving cannabis from Schedule I to Schedule III is a historic shift, but it isn’t a universal fix. From the multi-million-dollar 280E tax opportunity to the ongoing hurdles for adult-use operators, we break down the real business impact of the 2026 rescheduling order and why federal oversight is about to get a lot more complex.

The DEA isn’t stepping back; it’s stepping in. While the industry celebrates the end of 280E, the fine print of the new Schedule III order reveals a mandatory federal middleman, undisclosed fees, and a legal “prescription” trap that could leave dispensaries in limbo. Here is what the rescheduling order actually means for your bottom line.

A significant shift in federal law via H.R. 5371 threatens to recriminalize most hemp-derived THC products by November 12, 2026. Dubbed the “hemp-killing clause,” this provision sets a 0.4mg total THC cap per container, potentially turning compliant businesses into “real estate time bombs.” From auditing leases to negotiating early termination rights, two attorneys tackle how hemp tenants and landlords can navigate the looming regulatory crisis and protect their commercial interests before the “Hemp D-Day” deadline.

A potential move of cannabis to Schedule III could eventually reshape the industry’s tax burden by ending the reach of Section 280E. But operators should not confuse political momentum with immediate relief. A CPA explains why retroactive tax refunds are unlikely and disciplined compliance still matters. From defensible cost accounting to scenario planning and entity-structure review, the smartest path is cautious preparation rather than reactive change.

CDTFA reports California collected $255.1M in Q4 2025 cannabis taxes, down after Q3’s temporary rate spike.

According to a new report from Americans for Safe Access, impending federal changes to hemp definitions could strip access from veterans, seniors, and those with rare diseases who rely on full-spectrum products.

Rescheduling may bring long-awaited 280E relief and a new sheen of mainstream legitimacy, but it also opens the door to federal-grade oversight, GMP expectations, stricter lender requirements, and expanded liability exposure. The “extra” cash operators anticipate could be quickly absorbed by compliance upgrades, professional services, and risk management. For CEOs, COOs, and CFOs, reclassification isn’t a finish line. It’s the starting gun for a tougher operational race.

What cannabis rescheduling to Schedule III really means, how the process works, and why it matters for businesses and patients.

Rescheduling marijuana from Schedule I to Schedule III would not legalize cannabis — but it could fundamentally alter how the federal government treats the plant. From tax policy and medical research to regulatory oversight, here’s what cannabis rescheduling actually means, how the process works, and why it matters to businesses, patients, and policymakers.